Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiovascular

Set Alert for Cardiovascular

Farxiga Flying Off The Shelf At AstraZeneca

The UK major has raised its full-year sales and earnings forecast on strong demand in the second quarter for its cancer, rare disease and cardiovascular medicines.

Sales & Earnings Market Access

Boehringer Looks To Revitalise Its Pipeline

With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.

Sales & Earnings Companies

Cardurion Raises $260m To Advance First-In-Class Cardiovascular Drugs

The company’s series B venture capital will fund Phase IIb trials of PDE9 inhibitor CRD-750 in heart failure and a Phase IIa study of CaMKII inhibitor CRD-4730 in a rare arrhythmic disease.

Financing Cardiovascular

Arrowhead’s Focus On Plozasiran Intensifies Competition With Ionis

Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.

Cardiovascular Rare Diseases

Intellia Becomes First To Show Potential For CRISPR Therapy Re-Dosing

The company presented data showing it is possible to safely and effectively re-dose its ATTR amyloidosis CRISPR/Cas9-based therapy.

Gene Therapy Cardiovascular

Alnylam’s Amvuttra Market May See Tenfold Increase After Phase III Win

The company posted positive results from the HELIOS-B trial in patients with ATTR-CM, which represents a much larger population than the approved hATTR-PN indication.

Clinical Trials Cardiovascular

Cagrisema Leads The Charge For 2025

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.

Launches Companies

Aerovate Tanks On Trial Catastrophe

A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?

Clinical Trials Companies

First Phase III Success Opens Up Cardiovascular Pathway For Arrowhead

Arrowhead could have its first in-house RNA therapy on the market by 2025, with big plans to expand its reach in cardiometabolic disease, following a pivotal trial hit.

Companies Commercial

First Results Keep AstraZeneca’s Hopes High For Oral PCSK9 Inhibitor

AstraZeneca is looking to speed AZD0780 into Phase III development after it achieved a 78% total LDL cholesterol reduction in a Phase I study when used in combination with rosuvastatin. The firm needs to play catch up with its oral rivals.

Clinical Trials Companies

Cytokinetics’ Aficamten Data Could Be Best In Class, Cardiologists Say

The company released detailed data from the Phase III SEQUOIA-HCM trial testing the cardiac myosin inhibitor in patients with obstructive hypertrophic cardiomyopathy at Heart Failure 2024.

Cardiovascular Clinical Trials

Merck Investors Keeping A Close Watch On Winrevair Uptake

Some patients have already been prescribed the new drug for pulmonary arterial hypertension but Merck & Co. did not provide any sales or guidance. 

Sales & Earnings Launches
See All
UsernamePublicRestriction

Register